A Phase 3 interventional study of TAK-438 and Lansoprazole in Gastric Ulcer, sponsored by Takeda. Completed at 81 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-18.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.
Among the 10 studies testing vonoprazan in Stomach Ulcer, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 8 in phase 3, and was the 8th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:
Shicai Ye · Sites in China
Ages 18–70
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is below the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 320 across the 10 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
14 studies in Stomach Ulcer by Takeda: none open now, none under way, none of them phase 3. Of 14 finished, 6 (43%) have results posted.
Among the 14 studies in Stomach Ulcer by Takeda, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 11 in phase 3, and was the 13th registered.
Takeda’s Stomach Ulcer studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Stomach Ulcer, from their registry updates:
Among Takeda’s 14 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
The drug being tested in this study is called TAK-438. TAK-438 is being tested to treat people who have stomach ulcers and also may or may not have Helicobacter pylori (HP) infection. This study will look at stomach ulcer healing and also the elimination of HP in people who take TAK-438 versus lansoprazole.
The study will enroll approximately 830 patients.
Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need):
Study treatment will depend upon the Helicobacter pylori infection status of the participant, and include bismuth-containing quadruple therapy for the first 2 weeks in H pylori infected (HP+) participants. HP+ participants will be asked to take a TAK- 438 tablet or a lansoprazole capsule twice daily in conjunction with bismuth-containing quadruple therapy for 2 weeks, followed up by a TAK-438 tablet or a lansoprazole capsule once daily for up to 6 weeks. HP- participants will be asked to take a TAK-438 tablet or a lansoprazole capsule once daily for up to 8 weeks.
This multi-center trial will be conducted in China, Korea, Taiwan, and Philippines. The overall time to participate in this study is up to 12 weeks. Participants will make multiple visits plus final visit at 2 weeks or 4 weeks after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Laboratory tests performed prior to randomization revealed any of the following abnormalities in the participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Helicobacter Pylori positive (HP+) participants: TAK-438 20 mg tablet, twice daily (BID) along with lansoprazole placebo-matching, capsule BID in addition to bismuth-containing quadruple antibiotic therapy for the first 2 weeks. Following 2 weeks of eradication therapy participants received TAK-438 20 mg QD along with lansoprazole matching placebo 30 mg, capsule QD for up to 6 weeks. HP negative (HP-) participants: TAK-438 20 mg tablet, (QD) along with lansoprazole matching placebo, 30 mg capsule QD for up to 8 weeks.
Drug: TAK-438 · Drug: Lansoprazole Placebo · Drug: Bismuth-Containing Quadruple Therapy
HP+ participants: Lansoprazole 30 mg, capsule, orally, BID and TAK-438 placebo-matching tablet, orally, BID along with bismuth-containing quadruple antibiotic therapy for first 2 weeks. Following 2 weeks participants received Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 6 weeks. HP- participants: Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 8 weeks.
Drug: Lansoprazole · Drug: TAK-438 Placebo · Drug: Bismuth-Containing Quadruple Therapy
TAK-438 tablets
Also known as: Vonoprazan
Lansoprazole capsules
Also known as: Prevacid
TAK-438 placebo-matching tablets
Lansoprazole placebo-matching capsules
1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8
Endoscopic healing was defined as the disappearance of all white coats associated with GUs confirmed endoscopically.
Time frame: Week 4 or 8
Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 8 Weeks of Treatment
HP infection status was determined by 13C-UBT. The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The data is provided only for HP+ participants. The participant could take 4 or 8 weeks of treatment for GU healing, then additional 4 weeks later, to have the urea breath test (UBT) test to detect HP.
Time frame: 4 weeks post treatment (up to approximately 12 weeks)
Percentage of Participants With Endoscopically Confirmed Healing of GU at Week 4
Endoscopic healing was defined as the disappearance of all white coats associated with GUs confirmed endoscopically.
Time frame: Week 4
Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU
The gastrointestinal symptoms included epigastric pain \[postprandial, fasting, nocturnal\], abdominal bloating, nausea/vomiting, heartburn, lack of appetite. The severity of gastrointestinal symptoms associated with GU were recorded as: none = 0, mild = 1, moderate = 2 or severe = 3. The data is reported in categories for percentage of participants with resolution of gastrointestinal symptoms associated with GU.
Time frame: Week 2 up to Week 8
Participants took part in the study at 60 investigative sites in China, Korea, and Taiwan from 17 April 2017 to 26 May 2020.
| Milestone | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Started | 115 | 119 |
| Completed | 107 | 110 |
| Not completed | 8 | 9 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Significant protocol deviation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Voluntary withdrawal | 3 | 4 |
| Withdrew: Reason not specified | 1 | 1 |
Endoscopic healing was defined as the disappearance of all white coats associated with GUs confirmed endoscopically.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8 | 91.1 (84.193 to 95.635) | 94.7 (88.896 to 98.044) |
HP infection status was determined by 13C-UBT. The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The data is provided only for HP+ participants. The participant could take 4 or 8 weeks of treatment for GU healing, then additional 4 weeks later, to have the urea breath test (UBT) test to detect HP.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 8 Weeks of Treatment | 88.0 (78.439 to 94.363) | 80.8 (69.921 to 89.099) |
Endoscopic healing was defined as the disappearance of all white coats associated with GUs confirmed endoscopically.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Participants With Endoscopically Confirmed Healing of GU at Week 4 | 76.1 (67.035 to 83.788) | 82.1 (73.777 to 88.738) |
The gastrointestinal symptoms included epigastric pain \[postprandial, fasting, nocturnal\], abdominal bloating, nausea/vomiting, heartburn, lack of appetite. The severity of gastrointestinal symptoms associated with GU were recorded as: none = 0, mild = 1, moderate = 2 or severe = 3. The data is reported in categories for percentage of participants with resolution of gastrointestinal symptoms associated with GU.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Epigastric Pain (Postprandial) | 78.9 (54.435 to 93.948) | 80.0 (59.296 to 93.169) |
| Epigastric Pain (Fasting/Nocturnal) | 85.0 (70.165 to 94.290) | 80.5 (65.133 to 91.179) |
| Abdominal Bloating | 81.3 (54.354 to 95.953) | 65.2 (42.734 to 83.624) |
| Nausea/Vomiting | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Heartburn | 95.8 (78.880 to 99.895) | 85.7 (67.335 to 95.966) |
| Lack of Appetite | 77.8 (39.991 to 97.186) | 90.0 (55.498 to 99.747) |
Collected over From first dose up to 4 weeks post dose (up to approximately 12 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-438 20 mg | 0/115 (0%) | 3/115 (2.6%) | 43/115 (37.4%) |
| Lansoprazole 30 mg | 0/119 (0%) | 2/119 (1.7%) | 15/119 (12.6%) |
| Event | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| AppendicitisInfections and infestations | 1/115 | 0/119 |
| MeningitisInfections and infestations | 1/115 | 0/119 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/115 | 0/119 |
| Angina pectorisCardiac disorders | 0/115 | 1/119 |
| Liver abscessInfections and infestations | 0/115 | 1/119 |
| Event | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Pepsinogen test positiveInvestigations | 29/115 | 6/119 |
| Blood gastrin increasedInvestigations | 24/115 | 5/119 |
| Pepsinogen I increasedInvestigations | 23/115 | 8/119 |
| DysgeusiaNervous system disorders | 2/115 | 7/119 |
| Alanine aminotransferase increasedInvestigations | 6/115 | 3/119 |
All Randomized Participants.
| Age, Continuous(years) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 54.0 ± 13.68 | 53.5 ± 13.37 | 53.7 ± 13.50 |
| Sex: Female, Male(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Female | 29 | 27 | 56 |
| Male | 86 | 92 | 178 |
| Race (NIH/OMB)(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 114 | 119 | 233 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| China | 65 | 71 | 136 |
| Korea, Republic Of | 44 | 42 | 86 |
| Taiwan, Province Of China | 6 | 6 | 12 |
| Height(cm) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 165.4 ± 7.49 | 167.1 ± 7.96 | 166.2 ± 7.76 |
| Weight(kg) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 63.76 ± 10.743 | 66.83 ± 11.370 | 65.32 ± 11.149 |
| Body Mass Index(kg/m^2) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 23.25 ± 3.224 | 23.85 ± 3.255 | 23.56 ± 3.247 |
| Smoking classification(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| The Participant has Never Smoked | 49 | 52 | 101 |
| The Participant is a Current Smoker | 50 | 51 | 101 |
| The Participant is an Ex-smoker | 16 | 16 | 32 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: NOTE: IPD Sharing Time Frame has not been entered.
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2017 to primary completion in Feb 2020, 34 months.
Results were first posted in Jun 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vonoprazan · Lansoprazole